Compare ACU & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | PEPG |
|---|---|---|
| Founded | 1867 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.7M | 207.1M |
| IPO Year | 1994 | 2022 |
| Metric | ACU | PEPG |
|---|---|---|
| Price | $64.02 | $3.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $50.00 | $11.17 |
| AVG Volume (30 Days) | 27.9K | ★ 1.0M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | 1.63 | ★ 25.61 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $196,541,816.00 | N/A |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $43.71 | ★ N/A |
| Revenue Growth | ★ 1.05 | N/A |
| 52 Week Low | $35.50 | $1.30 |
| 52 Week High | $64.17 | $7.80 |
| Indicator | ACU | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 61.49 |
| Support Level | $39.97 | $1.47 |
| Resistance Level | N/A | $3.14 |
| Average True Range (ATR) | 2.24 | 0.21 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 91.82 | 35.25 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.